RVMD on Nasdaq
Revolution Medicines (United States)
American biological products company based in Redwood City, founded in 2014.1
Price unavailable
Last updated Oct 18, 2026.
Overview
2014Founded1
Compare with Caribou Biosciences, Inc., ELUTIA INC. or TScan Therapeutics, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Financial statements
Every line of the income statement as filed: the last 4 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total revenue | $0 | $0 | $11.6M | |
| Research and development | $987.3M | $592.2M | $423.1M | |
| General and administrative | $195.0M | $97.3M | $75.6M | |
| Total operating expenses | $1.2B | $689.5M | $498.8M | |
| Loss from operations | -$1.2B | -$689.5M | -$487.2M | |
| Interest income | $90.7M | $86.9M | $47.5M | |
| Interest expense | -$24.2M | $0 | $0 | |
| Change in fair value of warrant liability and contingent earn-out shares | -$15.4M | $4.3M | $115.0K | |
| Other expense, net: | -$37.0K | -$2.5M | -$303.0K | |
| Total non-operating income, net | $51.1M | $88.7M | $47.3M | |
| Income (loss) before provision for income taxes | -$1.1B | -$600.8M | -$439.9M | |
| Benefit from income taxes | $0 | $753.0K | $3.5M | |
| Net loss | -$1.1B | -$600.1M | -$436.4M | |
| Net loss per share attributable to common stockholders, basic | -$5.95 | -$3.58 | -$3.86 | |
| Net loss per share attributable to common stockholders, diluted | -$5.95 | -$3.58 | -$3.86 | |
| Weighted-average common shares used to compute net loss per share, basic | 190.1M shares | 167.7M shares | 113.1M shares | |
| Weighted-average common shares used to compute net loss per share, diluted | 190.1M shares | 167.7M shares | 113.1M shares | |
| Unrealized gain on investments, net | $1.9M | $777.0K | $2.3M | $2.3M |
| Comprehensive loss | -$1.1B | -$599.3M | -$434.0M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $383.7M | $543.1M | $696.1M | |
| Marketable securities | $1.6B | $1.7B | ||
| Prepaid expenses and other current assets | $49.4M | $38.3M | ||
| Total current assets | $2.1B | $2.3B | ||
| Property and equipment, net | $33.2M | $24.3M | ||
| Operating lease right-of-use asset | $132.1M | $117.5M | ||
| Intangible assets, net | $55.8M | $56.7M | ||
| Goodwill | $14.6M | $14.6M | ||
| Restricted cash | $4.9M | $3.7M | ||
| Long-term deposits | $24.1M | $12.1M | ||
| Other noncurrent assets | $14.8M | $1.7M | ||
| Total assets | $2.4B | $2.6B | ||
| Accounts payable | $64.6M | $54.4M | ||
| Accrued expenses and other current liabilities | $209.3M | $96.6M | ||
| Operating lease liability, current | $16.5M | $12.9M | ||
| Total current liabilities | $290.4M | $163.9M | ||
| Deferred tax liability | $2.4M | $2.4M | ||
| Operating lease liability, noncurrent | $142.2M | $123.0M | ||
| Liability related to the sale of future royalties | $268.4M | $0 | ||
| Warrant liability | $18.5M | $3.2M | ||
| Other noncurrent liabilities | $1.2M | $670.0K | ||
| Total liabilities | $723.2M | $293.1M | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; none issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $0 | $0 | ||
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 197,001,401 and 185,896,625 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $19.0K | $18.0K | ||
| Additional paid-in capital | $4.5B | $4.0B | ||
| Accumulated other comprehensive income | $3.2M | $1.3M | ||
| Accumulated deficit | -$2.9B | -$1.7B | ||
| Total stockholders' equity | $1.6B | $2.3B | $1.8B | $685.2M |
| Total liabilities and stockholders' equity | $2.4B | $2.6B | ||
| Preferred stock, par or stated value per share | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par or stated value per share | $0.00 | $0.00 | ||
| Common stock, shares authorized | 300.0M shares | 300.0M shares | ||
| Common stock, shares, issued | 197.0M shares | 185.9M shares | ||
| Common stock, shares, outstanding | 197.0M shares | 185.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $383.7M | $543.1M | $696.1M | |
| Marketable securities | $1.6B | $1.7B | ||
| Prepaid expenses and other current assets | $49.4M | $38.3M | ||
| Total current assets | $2.1B | $2.3B | ||
| Property and equipment, net | $33.2M | $24.3M | ||
| Operating lease right-of-use asset | $132.1M | $117.5M | ||
| Intangible assets, net | $55.8M | $56.7M | ||
| Goodwill | $14.6M | $14.6M | ||
| Restricted cash | $4.9M | $3.7M | ||
| Long-term deposits | $24.1M | $12.1M | ||
| Other noncurrent assets | $14.8M | $1.7M | ||
| Total assets | $2.4B | $2.6B | ||
| Accounts payable | $64.6M | $54.4M | ||
| Accrued expenses and other current liabilities | $209.3M | $96.6M | ||
| Operating lease liability, current | $16.5M | $12.9M | ||
| Total current liabilities | $290.4M | $163.9M | ||
| Deferred tax liability | $2.4M | $2.4M | ||
| Operating lease liability, noncurrent | $142.2M | $123.0M | ||
| Liability related to the sale of future royalties | $268.4M | $0 | ||
| Warrant liability | $18.5M | $3.2M | ||
| Other noncurrent liabilities | $1.2M | $670.0K | ||
| Total liabilities | $723.2M | $293.1M | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; none issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $0 | $0 | ||
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 197,001,401 and 185,896,625 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $19.0K | $18.0K | ||
| Additional paid-in capital | $4.5B | $4.0B | ||
| Accumulated other comprehensive income | $3.2M | $1.3M | ||
| Accumulated deficit | -$2.9B | -$1.7B | ||
| Total stockholders' equity | $1.6B | $2.3B | $1.8B | $685.2M |
| Total liabilities and stockholders' equity | $2.4B | $2.6B | ||
| Preferred stock, par or stated value per share | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par or stated value per share | $0.00 | $0.00 | ||
| Common stock, shares authorized | 300.0M shares | 300.0M shares | ||
| Common stock, shares, issued | 197.0M shares | 185.9M shares | ||
| Common stock, shares, outstanding | 197.0M shares | 185.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$1.1B | -$600.1M | -$436.4M |
| Loss on disposal of fixed assets | $32.0K | $118.0K | $52.0K |
| Amortization of intangible assets | $870.0K | $1.1M | $1.1M |
| Stock-based compensation expense | $118.4M | $79.2M | $61.8M |
| Depreciation and amortization | $7.8M | $6.6M | $5.0M |
| Change in fair value of warrant liability and contingent earn-out shares | $15.4M | -$4.3M | $115.0K |
| Non-cash interest expense on liabilities related to sale of future royalties | $24.2M | $0 | $0 |
| Net amortization of premium or discount on marketable securities | -$27.8M | -$44.6M | -$22.2M |
| Amortization of operating lease right-of-use asset | $7.9M | $4.2M | $3.2M |
| Accounts receivable | $0 | $1.3M | $3.4M |
| Prepaid expenses and other current assets | -$9.7M | -$9.7M | -$2.6M |
| Accounts payable | $9.5M | -$6.5M | $32.5M |
| Accrued expenses and other current liabilities | $112.3M | $22.0M | $14.7M |
| Deferred revenue | $0 | $0 | -$4.5M |
| Operating lease liability | -$957.0K | -$245.0K | -$1.5M |
| Deferred tax liability | $0 | -$762.0K | -$3.9M |
| Long-term deposits | -$12.0M | -$7.6M | -$2.3M |
| Other noncurrent assets | -$12.9M | $1.7M | $870.0K |
| Other noncurrent liabilities | $537.0K | $212.0K | $157.0K |
| Net cash used in operating activities | -$897.7M | -$557.4M | -$350.6M |
| Purchases of marketable securities | -$1.8B | -$2.1B | -$1.1B |
| Maturities of marketable securities | $1.9B | $1.6B | $724.0M |
| Sales of marketable securities | $6.4M | $0 | $0 |
| Purchases of property and equipment | -$16.0M | -$10.3M | -$7.7M |
| Net cash provided by (used in) investing activities | $118.1M | -$554.4M | -$342.6M |
| Cash, cash equivalents and restricted cash acquired in connection with EQRx Acquisition, net of transaction costs | $0 | $0 | $840.8M |
| Proceeds from the sale of future royalties, net of issuance costs | $244.2M | $0 | $0 |
| Proceeds from issuance of common stock, net of issuance costs | $0 | $727.6M | $323.7M |
| Proceeds from issuance of pre-funded warrants, net of transaction costs | $0 | $95.4M | $0 |
| Proceeds from issuance of common stock from at-the-market offering, net of transaction costs | $347.9M | $118.7M | $62.1M |
| Proceeds from issuance of common stock pursuant to stock option exercises | $21.1M | $12.3M | $3.3M |
| Proceeds from issuance of common stock related to employee stock purchase plan | $8.0M | $5.0M | $3.3M |
| Tax payment for common stock withheld in satisfaction of withholding tax requirements | $0 | $0 | -$4.0M |
| Exercise of warrants | $4.0K | $0 | $0 |
| Payments of deferred offering costs | $220.0K | $284.0K | $0 |
| Net cash provided by financing activities | $621.5M | $959.4M | $1.2B |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -$158.2M | -$152.4M | $536.0M |
| Issuance of common stock for EQRx acquisition | $0 | $0 | $1.1B |
| Fair value of net assets acquired in connection with EQRx Acquisition | $0 | $0 | $291.5M |
| Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities | $1.9M | $1.6M | $2.6M |
| Right-of-use assets obtained in exchange for operating lease liabilities | $22.5M | $44.6M | $25.3M |
No quarter-by-quarter statement was filed.
Compare Revolution Medicines (United States) with another company
Leadership
Who has led Revolution Medicines (United States), and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
201520202025
- Chief financial officerJack Anders Sep 2, 2022 to now12
- Chief operating officerMargaret A. Horn Nov 2, 2022 to now13
Board members and other officers (23)
- Chief Development OfficerAlan B. Sandler Mar 26, 2026 to now14
- OfficerAnthony Mancini Mar 26, 2026 to now15
- Chief Medical OfficerLin Wei Mar 29, 2024 to now16
- OfficerXiaolin Wang Mar 8, 2021 to now17
- OfficerJack Anders Feb 12, 2020 to Jun 22, 202218
- OfficerMargaret A. Horn Feb 12, 2020 to Mar 21, 202319
- OfficerMark A. Goldsmith Feb 12, 2020 to now20
- OfficerStephen Michael Kelsey Feb 12, 2020 to now21
- Board memberFrank Clyburn Aug 7, 2024 to now22
- Board memberSandra Horning Nov 14, 2023 to now23
- Board memberSushil Patel Jun 17, 2022 to now24
- Board memberLorence Kim Jul 13, 2022 to now25
- Board memberFlavia Borellini Jun 24, 2021 to now26
- Board memberAlexis Borisy Feb 12, 2020 to now27
- Board memberBarbara Weber Feb 12, 2020 to Oct 10, 202428
- Board memberElizabeth M. Anderson Feb 12, 2020 to now29
- Board memberLaurence Lasky Feb 12, 2020 to Feb 14, 202030
- Board memberMark A. Goldsmith Feb 12, 2020 to now20
- Board memberNeil Exter Feb 12, 2020 to Jun 17, 202231
- Board memberThilo Schroeder Feb 12, 2020 to Dec 9, 202432
- Board memberVincent A. Miller Feb 12, 2020 to Jun 24, 202133
- Board memberPeter Svennilson Jun 19, 2020 to Apr 28, 202134
- General counselJeff Cislini Mar 29, 2023 to now35
Timeline
- 2014Founded Founded1
Filings
664 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 57 major events, 300 insider forms, 51 large holders, 236 other. The latest 20:
- Oct 13, 20268-K EDGAR
- Oct 1, 20264 EDGAR
- Sep 29, 20264 EDGAR
- Sep 29, 2026144 EDGAR
- Sep 28, 20264 EDGAR
- Sep 25, 2026144 EDGAR
- Sep 24, 2026144 EDGAR
- Sep 24, 20264 EDGAR
- Sep 22, 20264 EDGAR
- Sep 22, 2026144 EDGAR
- Sep 18, 20264 EDGAR
- Sep 18, 20264 EDGAR
- Sep 18, 2026144 EDGAR
- Sep 18, 20264 EDGAR
- Sep 18, 20264 EDGAR
- Sep 18, 20264 EDGAR
- Sep 18, 20264 EDGAR
- Sep 18, 20264 EDGAR
- Sep 15, 2026144 EDGAR
- Sep 15, 2026144 EDGAR
The 664 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 51 such filings since October 2021, the latest 10:
- Aug 14, 2026SCHEDULE 13G
- Aug 13, 2026SCHEDULE 13G
- Aug 13, 2026SCHEDULE 13G/A
- Jul 29, 2026SCHEDULE 13G
- May 15, 2026SCHEDULE 13G/A
- Mar 27, 2026SCHEDULE 13G/A
- Feb 17, 2026SCHEDULE 13G/A
- Feb 10, 2026SCHEDULE 13G/A
- Feb 9, 2026SCHEDULE 13G/A
- Nov 14, 2025SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 13,695,790 | $2.6B | 0.0% | +2,483,084 |
| Farallon Capital Management, L.l.c. | 13,550,796 | $2.5B | 15.0% | −54,000 |
| Fmr LLC | 12,200,422 | $2.3B | 0.1% | +3,736,108 |
| Baker Bros. Advisors LP | 11,443,357 | $2.1B | 10.8% | +1,888,000 |
| Darwin Global Management, Ltd. | 10,629,822 | $2.0B | 54.5% | +8,418,804 |
| Jupiter Topco LLC | 10,736,145 | $2.0B | 0.8% | New |
| Vanguard Capital Management LLC | 9,088,661 | $1.7B | 0.0% | +726,377 |
| Vanguard Portfolio Management LLC | 8,294,855 | $1.6B | 0.1% | +792,232 |
| Nextech Invest Ltd. | 7,601,087 | $1.4B | 67.6% | No change |
| Paradigm Biocapital Advisors LP | 6,361,323 | $1.2B | 22.3% | −294,380 |
| UBS Group AG | 5,448,364 | $1.0B | 0.2% | +1,061,573 |
| State Street Corp | 4,897,051 | $917.1M | 0.0% | +494,389 |
| Capital World Investors | 4,008,244 | $750.7M | 0.1% | New |
| Geode Capital Management, LLC | 3,942,676 | $736.8M | 0.0% | +604,534 |
| Wellington Management Group Llp | 3,843,415 | $719.8M | 0.1% | −2,184,404 |
| Jpmorgan Chase & Co | 3,298,066 | $636.9M | 0.0% | +2,996,673 |
| Bvf Inc/il | 2,965,160 | $555.3M | 14.2% | +108,378 |
| Alphabet Inc. | 2,946,619 | $551.8M | 0.6% | −345,906 |
| Casdin Capital, LLC | 2,577,333 | $482.7M | 24.2% | No change |
| Deerfield Management Company, L.P. | 2,392,000 | $448.0M | 5.6% | +95,000 |
| Avoro Capital Advisors LLC | 2,297,000 | $430.2M | 3.9% | −47,444 |
| Norges Bank | 2,157,479 | $404.1M | 0.0% | New |
| Goldman Sachs Group Inc | 2,133,101 | $399.5M | 0.0% | −52,399 |
| Nearwater Capital Markets, Ltd | 2,097,000 | $392.7M | 6.8% | +1,419,000 |
| Massachusetts Financial Services Co /ma/ | 2,012,317 | $376.8M | 0.1% | New |
13F reports cover disclosed long positions in U.S. stocks only.
Links
- Websitewww.revmed.com1
- WikidataQ107518109
- SEC EDGARCIK 1628171
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARJack Anders, Chief financial officer
- 13
- 14
- 15SEC EDGARAnthony Mancini, Officer
- 16SEC EDGARLin Wei, Chief Medical Officer
- 17SEC EDGARXiaolin Wang, Officer
- 18SEC EDGARJack Anders, Officer
- 19SEC EDGARMargaret A. Horn, Officer
- 20SEC EDGARMark A. Goldsmith, Officer
- 21SEC EDGARStephen Michael Kelsey, Officer
- 22SEC EDGARFrank Clyburn, Board member
- 23SEC EDGARSandra Horning, Board member
- 24SEC EDGARSushil Patel, Board member
- 25SEC EDGARLorence Kim, Board member
- 26SEC EDGARFlavia Borellini, Board member
- 27SEC EDGARAlexis Borisy, Board member
- 28SEC EDGARBarbara Weber, Board member
- 29SEC EDGARElizabeth M. Anderson, Board member
- 30SEC EDGARLaurence Lasky, Board member
- 31SEC EDGARNeil Exter, Board member
- 32SEC EDGARThilo Schroeder, Board member
- 33SEC EDGARVincent A. Miller, Board member
- 34SEC EDGARPeter Svennilson, Board member
- 35SEC EDGARJeff Cislini, General counsel